EHP's cannabinopropol derivative oral preparation EFDA-101 to treat systemic sclerosis, fda edified by FDA

Emerald Health Pharmaceuticals (EHP)clinicalmajor candidate EHP-101, which is certified by the U.SFood and DrugManagementAgency for the treatment of systemic sclerosis (SSc)EHP-101 is a new synthetic derivative of cannabidiol (CBD) oral formulation, which has the activity of the dual peroxidase proliferation receptor gamma (PPAR) and type 2 cannabinoid receptor (CB2)Both receptors are therapeutic targets for SScEHP-101 has been awarded the title of "orphan drug" for SSc in the United States and the European Union, and the active pharmaceutical ingredient in EHP-101 is considered by the U.SDrug Control Agency (DEA) to be not a controlled substanceJim DeMesa, M.D., President and CEO ofEmerald Health Pharmaceuticals, said: "As Phase II begins, fast-track designations and previous lyncantitles for orphan drugs provide us with the most effective regulatory approach toclinicaldevelopment programssystemic sclerosis (SSc) is a serious form of sclerecara, a rare chronic auto
immune disease that causes fibrosis of the skin and internal organs and damage to blood vessels The tissues of the affected organs harden and fibrosis, resulting in their reduced function The disease is more common in adults, with an estimated 80,000-100,000 patients in the United States, and there is currently no approved treatment for SSc